Navigation Links
WellSpring Pharmaceutical Corp. Names Wendy Shusko as New Chief Operating Officer
Date:10/28/2008

BRADENTON, Fla., Oct. 28 /PRNewswire/ -- WellSpring Pharmaceutical Corporation, a growing North American-based pharmaceutical manufacturer, today announced that Wendy Shusko has been named Chief Operating Officer. Formerly, Ms. Shusko held the position of Chief Financial Officer, having joined the company in early 2000. In her new role as COO, Ms. Shusko will maintain financial responsibilities while broadening her areas of oversight to operations with an initial focus on the newly acquired consumer brands product line.

"WellSpring has been successful in the relaunch of older niche prescription products. We now have the opportunity to show equal success with our new niche consumer products portfolio," said Ms. Shusko. "I am looking forward to the challenge and am pleased to be able to take part in WellSpring's continued growth."

Ms. Shusko has over twenty years' experience of combined financial and operational experience with sixteen of those years in the pharmaceutical industry. From 1992 until joining the WellSpring team, Ms. Shusko worked in various management and financial capacities for Roberts Pharmaceutical Corporation, an international, multi-faceted pharmaceutical company, including Director of Finance and Financial Operations.

"WellSpring's success thus far can be attributed to driven efforts toward a common vision. I am now asking Ms. Shusko to apply her experience and skills to operations with the anticipation that we will continue that trend in the years to come," said Dr. Robert A. Vukovich, WellSpring's CEO and Chairman.

About the Company

WellSpring Pharmaceutical Corp has made the development, marketing and sales of new and novel prescription and OTC drug products its strategic focus. WellSpring's prescription drug products include Dyrenium (R) (diuretic) and Dibenzyline (R) (anti-hypertension) which are marketed in the US. The firm is an active acquirer of pharmaceutical brands and enhances their value through the development of product improvements and line extensions.

WellSpring is a privately held pharmaceutical company founded in 1999 by Dr. Robert A. Vukovich, the firm's CEO and Chairman. Dr. Vukovich previously founded and managed Roberts Pharmaceutical Corporation of Eatontown, NJ until its acquisition by Shire Pharmaceutical Group in 1999. WellSpring owns and operates an FDA approved manufacturing plant in Oakville, Ontario, Canada. Its administrative headquarters are located in Bradenton, Florida. The firm provides contract manufacturing services to the pharmaceutical industry and manufactures prescription and OTC drug products for both the US and Canada.

Contact: Dr. Robert A. Vukovich, +1-941-552-7880, or +1-941-504-1229, or Wendy Shusko, +1-941-552-7881.

WellSpring Websites: http://www.wellspringpharm.com, http://www.wpcoutsourcing.com, http://www.wellskin.ca.


'/>"/>
SOURCE WellSpring Pharmaceutical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WellSpring Pharmaceutical Corp. Acquires Consumer Product Brands from McNeil Consumer Healthcare -- Deal Enhances US and Canadian Pharmaceutical Business
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
7. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... at 9618 Huebner Road. The clinic is the group’s 7th location in San Antonio ... Ali Higgins, PT, will provide care from the clinic, which opened March 22, 2017. ...
(Date:3/24/2017)... ... March 24, 2017 , ... As the standards bearer of ... platform that positions them as the go-to thought leader in all matters concerning ... as an always-on, always-fresh news, views and advocacy engine, called ONS Voice. , ...
(Date:3/24/2017)... ... 24, 2017 , ... Gastro Health (“GH”) ( http://www.gastrohealth.com ... for colonoscopy at the HyGIeaCare® Center that is to be located adjacent to ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration (FDA), ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... “Vintage and ... a retired minister and college Bible teacher residing in North Carolina with his wife, ... who have blessed them with six grandchildren. David is also the author of “Shadow ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... ShangPharma, a leading life science ... development and discovery services, technology, and investment ... today the intent for a strategic corporate ... the Contract Research Organizations (CRO) and Contract ... entities include ChemPartner Shanghai, ChemPartner Fengxian, ChemPartner ...
(Date:3/24/2017)... , March 24, 2017 A ReportsnReports.com report ... been growing rapidly as the global sales of Adcetris and Kadcyla ... in the antibody drug conjugates market is driven by large number ... and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly ... announced plans to invest $850 million in its ... facilities across its U.S. enterprise, including research laboratories, ... investments are being driven by demand for Lilly ... potential medicines in development targeting cancer, pain, diabetes ...
Breaking Medicine Technology: